1. China Stocks

  2. •

    Technology services

  3. •

    Information technology services
Beijing Airdoc Technology Co. Ltd. Class H

Beijing Airdoc Technology Co. Ltd. Class H

HHKEX:2251
8.60
HKD
-0.70
(-7.53%)
1.27BMarket Cap
Apr 01Next Earn
Beijing Airdoc Technology Co. Ltd. Class H
HKEX:2251
(Hong Kong Exchange)

Recent

price

8.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.29
0.46
1.42
1.1
1.97
1.53
1.69
- -
Revenue per Share
-0.84
-0.77
-1.76
-1.75
-1.28
-2.5
-0.24
- -
Basic EPS, GAAP
-0.59
-0.63
-1.73
-3.81
0.08
-1.64
-0.23
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.54
3.94
17.98
16.09
15.02
12.28
11.98
12.28
Book Value per Share
-1.54
3.94
17.98
16.02
12.86
10.64
10.44
10.64
Tangible Book Value per Share
104
104
81
103
104
102
102
102
Basic Weighted Avg Shares
30
48
115
114
204
156
173
- -
Sales/Revenue/Turnover
-171.15
-118.85
-122.22
-206.18
-90.41
-127.06
-16.11
- -
Operating Margin (%)
3
5
15
23
32
27
21
- -
Depreciation Expense
-87
-80
-143
-180
-133
-255
-25
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-286.5
-167.95
-123.83
-158.37
-64.98
-163.37
-14.41
- -
Profit Margin (%)
-163
384
1,775
1,611
1,172
772
717
772
Working Capital
- -
- -
3
4
1
- -
3
- -
LT Debt
-159
408
1,820
1,671
1,558
1,277
1,222
1,277
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
-12.8
-10.33
-8.27
-18.19
-2
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
ST Debt
9
3
32
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
103
104
103
Market Capitalization
1,128
1,378
1,197

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Jun'24
Dec'24
Total Current Assets
1,282
1,018
894
Cash, Cash Equivalents & STI
1,142
908
775
Accounts Receivable, Net
80
58
46
Inventories
40
28
31
Total Current Liabilities
110
62
122
Payables & Accruals
- -
- -
- -
ST Debt
9
3
32
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.66%
-4.25%
Free Cash Flow
- -
-415.82%
-85.74%
Net Income, GAAP
- -
16.1%
-90.22%
Sales/Revenue/Turnover
- -
41.44%
10.8%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
204
2024
- -
- -
156
2025
- -
- -
173

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.28
2024
- -
- -
-2.5
2025
- -
- -
-0.24

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Credo Technology Group Holding Ltd (NASDAQ:CRDO)
Tata Consultancy Services Limited (NSE:TCS)
International Business Machines Corporation (NYSE:IBM)
Infosys Limited (NSE:INFY)
HCL Technologies Limited (NSE:HCLTECH)
Cloudflare, Inc. (NYSE:NET)
Business
Beijing Airdoc Technology Co., Ltd. (2251.HK) develops and provides AI-empowered retina-based early detection, diagnosis, health risk assessment, and treatment solutions for chronic and ophthalmic diseases; its core products include the Airdoc-AIFUNDUS SaMD series (Versions 1.0, 2.0, and 3.0) for diabetic retinopathy, hypertensive retinopathy, glaucoma, cataracts, pathological myopia, retinal detachment, and other fundus diseases; health risk assessment solutions covering 55 types of lesions and risks such as cardiovascular disease, anemia, dementia, and atrial fibrillation; AI-powered hardware like the AI-FUNDUSCAMERA-P portable fundus cameras, AI-FUNDUSCAMERA-M multimodal scanner, and in-house fundus cameras; myopia prevention products featuring PBM-LED light therapy devices and AI-driven intervention solutions; and visual training AI products with eye-tracking and personalized modules for strabismus, amblyopia, and vision rehabilitation, including all-in-one digital training machines and Vision Box hardware. Founded in 2015 and headquartered in Beijing, China, the company operates primarily in mainland China through subsidiaries and R&D centers in Shanghai, Guangzhou, Shenzhen, Hong Kong, Nanjing, Xi'an, Chengdu, and Wuhan, with expanding international presence in the European Union, Singapore, Thailand, Indonesia, Vietnam, South Africa, Saudi Arabia, the United Arab Emirates, and Malaysia via regulatory approvals for key products. It serves hospitals, primary healthcare institutions, health checkup centers, consumer healthcare settings like insurance firms and pharmacies, optometry centers, and eye health management platforms, targeting clinical departments, chronic disease screening, and pediatric vision care. Recent developments include the 2024 launch and January 2025 NMPA Class II certification of a new portable AI-optimized fundus camera for home and small B-end markets; NMPA approval in December 2024 for the pioneering PBM-LED myopia light therapy device and fundus function updates for AI-FUNDUSCAMERA-M in August 2024; submission of Airdoc-AIFUNDUS 2.0 registration in Q4 2024; a April 2024 partnership enhancing health services; deployment of WanYu Large Language Model-powered AI digital human "ikkie" with iKang; 40 new patents granted in 2024, totaling 270; and growth to 7,883 active service sites with 7.10 million cases served.